- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.20 Å
- Oligo State
- homo-dimer
- Ligands
- 3 x NAG- NAG- BMA- FUC: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-3)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- FUC- NAG: alpha-L-fucopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x ZN: ZINC ION(Non-covalent)
ZN.6: 6 residues within 4Å:- Chain A: D.162, D.191, N.228, H.313, H.350
- Ligands: FE.7
4 PLIP interactions:3 interactions with chain A, 1 Ligand-Water interactions- Metal complexes: A:D.191, A:H.313, A:H.350, H2O.10
ZN.18: 6 residues within 4Å:- Chain B: D.162, D.191, N.228, H.313, H.350
- Ligands: FE.19
4 PLIP interactions:3 interactions with chain B, 1 Ligand-Water interactions- Metal complexes: B:D.191, B:H.313, B:H.350, H2O.18
- 2 x FE: FE (III) ION(Non-covalent)
FE.7: 7 residues within 4Å:- Chain A: D.162, D.191, Y.194, H.229, H.350, H.352
- Ligands: ZN.6
5 PLIP interactions:4 interactions with chain A, 1 Ligand-Water interactions- Metal complexes: A:D.162, A:D.191, A:Y.194, A:H.352, H2O.10
FE.19: 6 residues within 4Å:- Chain B: D.162, D.191, Y.194, H.350, H.352
- Ligands: ZN.18
5 PLIP interactions:4 interactions with chain B, 1 Ligand-Water interactions- Metal complexes: B:D.162, B:D.191, B:Y.194, B:H.352, H2O.18
- 4 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.8: 6 residues within 4Å:- Chain A: M.38, D.43, V.44, F.167, N.170, S.174
7 PLIP interactions:7 interactions with chain A- Hydrophobic interactions: A:F.167
- Hydrogen bonds: A:D.43, A:D.43, A:S.174
- Water bridges: A:D.43, A:D.43, A:S.174
NAG.20: 1 residues within 4Å:- Chain B: N.108
No protein-ligand interaction detected (PLIP)NAG.21: 7 residues within 4Å:- Chain B: M.38, S.42, D.43, V.44, F.167, N.170, S.174
6 PLIP interactions:6 interactions with chain B- Hydrophobic interactions: B:F.167
- Hydrogen bonds: B:D.43, B:D.43, B:N.170, B:S.174
- Water bridges: B:D.43
NAG.31: 2 residues within 4Å:- Chain B: P.235, N.238
No protein-ligand interaction detected (PLIP)- 11 x SO4: SULFATE ION(Non-functional Binders)
SO4.9: 3 residues within 4Å:- Chain A: R.67, K.123, Y.124
2 PLIP interactions:2 interactions with chain A- Hydrogen bonds: A:Y.124
- Salt bridges: A:R.67
SO4.10: 9 residues within 4Å:- Chain A: G.284, R.285, K.333
- Chain B: Y.280, Y.283, S.314, E.326
- Ligands: SO4.11, NA.22
7 PLIP interactions:5 interactions with chain B, 2 interactions with chain A- Hydrogen bonds: B:Y.283, B:S.314, B:E.326, A:R.285
- Water bridges: B:S.279, B:A.329
- Salt bridges: A:K.333
SO4.11: 5 residues within 4Å:- Chain A: R.285, Y.290, K.333
- Chain B: E.326
- Ligands: SO4.10
4 PLIP interactions:3 interactions with chain A, 1 interactions with chain B- Hydrogen bonds: A:Y.290
- Water bridges: A:K.333, B:M.325
- Salt bridges: A:K.333
SO4.12: 4 residues within 4Å:- Chain A: V.300, K.301, R.302, S.303
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:R.302, A:S.303
- Salt bridges: A:K.301
SO4.13: 4 residues within 4Å:- Chain A: K.422, W.446
- Ligands: NAG-NAG-BMA-FUC.3, NAG-NAG-BMA-FUC.3
No protein-ligand interaction detected (PLIP)SO4.14: 4 residues within 4Å:- Chain A: M.399, Q.401, Q.403, R.410
4 PLIP interactions:4 interactions with chain A- Hydrogen bonds: A:Q.401
- Water bridges: A:Q.403, A:R.410
- Salt bridges: A:R.410
SO4.15: 2 residues within 4Å:- Chain A: L.151, R.424
1 PLIP interactions:1 interactions with chain A- Salt bridges: A:R.424
SO4.16: 2 residues within 4Å:- Chain A: K.94, R.140
2 PLIP interactions:2 interactions with chain A- Salt bridges: A:K.94, A:R.140
SO4.24: 4 residues within 4Å:- Chain B: S.88, N.91, R.95, K.123
5 PLIP interactions:5 interactions with chain B- Hydrogen bonds: B:S.88, B:N.91
- Water bridges: B:S.88, B:R.93
- Salt bridges: B:R.95
SO4.25: 1 residues within 4Å:- Chain B: R.433
5 PLIP interactions:5 interactions with chain B- Water bridges: B:E.411, B:R.433, B:R.433, B:R.433
- Salt bridges: B:R.433
SO4.26: 4 residues within 4Å:- Chain B: N.35, R.197, Y.198, P.199
5 PLIP interactions:5 interactions with chain B- Hydrogen bonds: B:N.35, B:R.197
- Water bridges: B:N.35, B:R.197, B:R.197
- 5 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.17: 4 residues within 4Å:- Chain A: R.424, T.425, W.452
- Ligands: NAG-NAG-BMA-FUC.3
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:R.424
- Water bridges: A:R.424, A:R.424
EDO.27: 2 residues within 4Å:- Chain B: K.94, R.140
4 PLIP interactions:4 interactions with chain B- Hydrogen bonds: B:K.94, B:K.94, B:R.140, B:R.140
EDO.28: 3 residues within 4Å:- Chain B: N.321, H.322, N.398
2 PLIP interactions:2 interactions with chain B- Water bridges: B:H.322, B:D.396
EDO.29: 3 residues within 4Å:- Chain B: Q.401, Q.403, R.410
4 PLIP interactions:4 interactions with chain B- Hydrogen bonds: B:Q.401, B:Q.403, B:R.410
- Water bridges: B:R.410
EDO.30: 3 residues within 4Å:- Chain A: E.326
- Chain B: Y.290, K.333
3 PLIP interactions:2 interactions with chain B, 1 interactions with chain A- Hydrogen bonds: B:K.333
- Water bridges: B:R.285, A:F.324
- 2 x NA: SODIUM ION(Non-functional Binders)
NA.22: 5 residues within 4Å:- Chain B: Y.280, S.314, E.326, H.350
- Ligands: SO4.10
2 PLIP interactions:2 interactions with chain B- Hydrogen bonds: B:S.314, B:H.350
NA.23: 4 residues within 4Å:- Chain A: E.326
- Chain B: G.284, R.285, K.333
5 PLIP interactions:3 interactions with chain B, 2 interactions with chain A- Hydrogen bonds: B:R.285, B:K.333, B:K.333
- Water bridges: A:E.326, A:A.329
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Feder, D. et al., Synthesis, evaluation and structural investigations of potent purple acid phosphatase inhibitors as drug leads for osteoporosis. Eur.J.Med.Chem. (2019)
- Release Date
- 2019-09-04
- Peptides
- Fe(3+)-Zn(2+) purple acid phosphatase: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
BB
C
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.20 Å
- Oligo State
- homo-dimer
- Ligands
- 3 x NAG- NAG- BMA- FUC: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-3)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- FUC- NAG: alpha-L-fucopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x ZN: ZINC ION(Non-covalent)
- 2 x FE: FE (III) ION(Non-covalent)
- 4 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 11 x SO4: SULFATE ION(Non-functional Binders)
- 5 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- 2 x NA: SODIUM ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Feder, D. et al., Synthesis, evaluation and structural investigations of potent purple acid phosphatase inhibitors as drug leads for osteoporosis. Eur.J.Med.Chem. (2019)
- Release Date
- 2019-09-04
- Peptides
- Fe(3+)-Zn(2+) purple acid phosphatase: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
BB
C